- Cognition Therapeutics (CGTX, Financial) reports promising Phase 2 results for its drug zervimesine in treating dementia with Lewy bodies (DLB).
- In the SHIMMER study, zervimesine improved behavioral symptoms by 86% and motor symptoms by 62% compared to placebo.
- The SHINE study showed zervimesine slows cognitive decline by 95% in Alzheimer's patients with low p-Tau217 levels.
Cognition Therapeutics, Inc. (CGTX) has announced significant positive outcomes from its Phase 2 'SHIMMER' study for its drug zervimesine (CT1812) in treating dementia with Lewy bodies (DLB). The study showcased notable improvements in various symptoms, including an 86% enhancement in behavioral outcomes, a 52% increase in daily living activities, a 91% improvement in cognitive fluctuations, and a 62% amelioration in motor symptoms compared to placebo.
The dual efficacy of zervimesine was further evidenced in the Phase 2 'SHINE' study for Alzheimer's disease, where it demonstrated a 95% reduction in cognitive decline over six months for patients with lower p-Tau217 levels compared to those on placebo. Dr. James E. Galvin is set to present these findings at the Alzheimer's Association International Conference (AAIC) on July 29, 2025.
DLB, affecting approximately 1.4 million Americans, currently lacks approved disease-modifying therapies. This new data offers hope, showcasing zervimesine's potential as a once-daily oral treatment, addressing the full spectrum of DLB’s diverse symptoms, including neuropsychiatric and motor symptoms, cognitive impairments, and attention fluctuations.
Cognition Therapeutics, a clinical-stage firm, aims to continue leveraging zervimesine's neuroprotective mechanism in future studies, providing further insights into its efficacy and optimal patient selection strategies. The company's continued research and anticipated presentations at the AAIC underscore the drug's potential impact on neurodegenerative disorder treatment.
